Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
NBIX's Cash to Debt is ranked higher than
95% of the 926 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. NBIX: No Debt )
NBIX' s 10-Year Cash to Debt Range
Min: 3.4   Max: No Debt
Current: No Debt

Interest Coverage No Debt
NBIX's Interest Coverage is ranked higher than
98% of the 566 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 160.63 vs. NBIX: No Debt )
NBIX' s 10-Year Interest Coverage Range
Min: 2.5   Max: 9999.99
Current: No Debt

2.5
9999.99
F-Score: 2
Z-Score: 47.98
M-Score: -3.19
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -8823.42
NBIX's Operating margin (%) is ranked lower than
54% of the 875 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.10 vs. NBIX: -8823.42 )
NBIX' s 10-Year Operating margin (%) Range
Min: -17340.03   Max: 43.82
Current: -8823.42

-17340.03
43.82
Net-margin (%) -8293.42
NBIX's Net-margin (%) is ranked lower than
54% of the 875 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.05 vs. NBIX: -8293.42 )
NBIX' s 10-Year Net-margin (%) Range
Min: -16936.19   Max: 48.53
Current: -8293.42

-16936.19
48.53
ROE (%) -29.19
NBIX's ROE (%) is ranked higher than
55% of the 895 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.83 vs. NBIX: -29.19 )
NBIX' s 10-Year ROE (%) Range
Min: -250.63   Max: 94.61
Current: -29.19

-250.63
94.61
ROA (%) -25.14
NBIX's ROA (%) is ranked higher than
54% of the 930 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.82 vs. NBIX: -25.14 )
NBIX' s 10-Year ROA (%) Range
Min: -62.22   Max: 26.57
Current: -25.14

-62.22
26.57
ROC (Joel Greenblatt) (%) -3036.25
NBIX's ROC (Joel Greenblatt) (%) is ranked lower than
51% of the 925 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.02 vs. NBIX: -3036.25 )
NBIX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3011.27   Max: 2175.88
Current: -3036.25

-3011.27
2175.88
Revenue Growth (3Y)(%) -100.00
NBIX's Revenue Growth (3Y)(%) is ranked lower than
53% of the 742 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.40 vs. NBIX: -100.00 )
NBIX' s 10-Year Revenue Growth (3Y)(%) Range
Min: -100   Max: 175.9
Current: -100

-100
175.9
» NBIX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

NBIX Guru Trades in Q1 2014

Pioneer Investments 434,514 sh (-17.16%)
» More
Q2 2014

NBIX Guru Trades in Q2 2014

Pioneer Investments 511,617 sh (+17.74%)
» More
Q3 2014

NBIX Guru Trades in Q3 2014

Pioneer Investments 503,938 sh (unchged)
» More
Q4 2014

NBIX Guru Trades in Q4 2014

Pioneer Investments 238,621 sh (-52.65%)
» More
» Details

Insider Trades

Latest Guru Trades with NBIX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2013-09-30 Sold Out 0.03%$10.6 - $16.7 $ 39.05183%0
George Soros 2013-06-30 New Buy0.03%$10.9 - $13.57 $ 39.05218%200000
Joel Greenblatt 2012-12-31 Sold Out 0.13%$6.88 - $8.66 $ 39.05414%0
Joel Greenblatt 2012-06-30 Add 23.8%0.03%$6.31 - $8.06 $ 39.05444%259903
George Soros 2012-06-30 Sold Out 0.02%$6.31 - $8.06 $ 39.05444%0
Joel Greenblatt 2012-03-31 New Buy0.15%$7.33 - $9.79 $ 39.05391%209930
George Soros 2012-03-31 New Buy0.02%$7.33 - $9.79 $ 39.05391%150000
George Soros 2011-12-31 Sold Out 0.0018%$5.5 - $8.58 $ 39.05478%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 14.20
NBIX's P/B is ranked higher than
52% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.57 vs. NBIX: 14.20 )
NBIX' s 10-Year P/B Range
Min: 0.9   Max: 108
Current: 14.2

0.9
108
Current Ratio 12.65
NBIX's Current Ratio is ranked higher than
95% of the 900 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.36 vs. NBIX: 12.65 )
NBIX' s 10-Year Current Ratio Range
Min: 2.52   Max: 17.59
Current: 12.65

2.52
17.59
Quick Ratio 12.65
NBIX's Quick Ratio is ranked higher than
96% of the 900 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.83 vs. NBIX: 12.65 )
NBIX' s 10-Year Quick Ratio Range
Min: 2.52   Max: 17.59
Current: 12.65

2.52
17.59

Valuation & Return

vs
industry
vs
history
Price/Net Cash 18.69
NBIX's Price/Net Cash is ranked higher than
89% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. NBIX: 18.69 )
NBIX' s 10-Year Price/Net Cash Range
Min: 3.67   Max: 254.67
Current: 18.69

3.67
254.67
Price/Net Current Asset Value 18.69
NBIX's Price/Net Current Asset Value is ranked higher than
83% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. NBIX: 18.69 )
NBIX' s 10-Year Price/Net Current Asset Value Range
Min: 3.5   Max: 84.89
Current: 18.69

3.5
84.89
Price/Tangible Book 14.20
NBIX's Price/Tangible Book is ranked higher than
57% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.29 vs. NBIX: 14.20 )
NBIX' s 10-Year Price/Tangible Book Range
Min: 1.25   Max: 30.22
Current: 14.2

1.25
30.22
Price/DCF (Projected) 162.70
NBIX's Price/DCF (Projected) is ranked higher than
72% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.24 vs. NBIX: 162.70 )
NBIX' s 10-Year Price/DCF (Projected) Range
Min: 9.63   Max: 93.08
Current: 162.7

9.63
93.08
Earnings Yield (Greenblatt) -2.30
NBIX's Earnings Yield (Greenblatt) is ranked higher than
59% of the 927 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. NBIX: -2.30 )
NBIX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 3683.9
Current: -2.3

0.2
3683.9

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:NB3.Germany,
Neurocrine Biosciences, Inc., a California corporation was incorporated in January 1992 and was reincorporated in Delaware in May 1996. The Company discovers, develops and commercializes drugs for the treatment of neurological and endocrine-related diseases and disorders. Its product candidates address pharmaceutical markets internationally, including insomnia, anxiety, depression, various female and male health disorders, multiple sclerosis, diabetes and other neurological and endocrine related diseases and disorders. The Company's two late-stage clinical programs are elagolix, a GnRH antagonist in Phase III development for endometriosis and Phase II clinical studies of uterine fibroids that is partnered with AbbVie, and a wholly owned VMAT2 inhibitor for the treatment of movement disorders that is currently in Phase II development. Its clinical development program, elagolix, is a drug candidate for the treatment of endometriosis and uterine fibroids. The Company faces competition from biotechnology and pharmaceutical companies, research institutions, government agencies and academic institutions.
» More Articles for NBIX

Headlines

Articles On GuruFocus.com
Weekly Insider Sells Highlight: ORCL, TWC, FB, NBIX Jan 13 2014 
5 Strong Healthcare Stocks For 2012 Mar 24 2012 
Consider These 5 Healthcare Stocks Now Mar 21 2012 
Neurocrine Biosciences Inc. (NBIX) VP and CFO Timothy P Coughlin sells 12,320 Shares Mar 02 2011 
Neurocrine Biosciences Inc. (NBIX) President and CEO Kevin Charles Gorman sells 15,400 Shares Mar 02 2011 
Neurocrine Biosciences Inc. Reports Operating Results (10-Q) Oct 29 2010 
Neurocrine Biosciences Inc. Reports Operating Results (10-Q) Jul 29 2010 
Neurocrine Biosciences Inc. Reports Operating Results (10-Q) Apr 29 2010 
Neurocrine Biosciences Inc. (NBIX) VP and CFO Timothy P Coughlin sells 12,650 Shares Mar 03 2010 
Neurocrine Biosciences Inc. (NBIX) President and CEO Kevin Charles Gorman sells 15,609 Shares Mar 03 2010 

More From Other Websites
Neurocrine Biosciences to Present at Cowen and Company's 35th Annual Health Care Conference Feb 24 2015
Neurocrine Biosciences to Present at Cowen and Company's 35th Annual Health Care Conference Feb 24 2015
Neurocrine Biosciences, Inc. Announces Exercise in Full of Underwriters' Option to Purchase... Feb 20 2015
NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Feb 19 2015
Neurocrine Biosciences, Inc. Prices Public Offering of Common Stock Feb 19 2015
Neurocrine Biosciences, Inc. Prices Public Offering of Common Stock Feb 19 2015
Neurocrine Biosciences Announces New Offering Feb 18 2015
Neurocrine Biosciences, Inc. Announces Proposed Public Offering of $225 Million of Common Stock Feb 17 2015
Neurocrine Biosciences, Inc. Announces Proposed Public Offering of $225 Million of Common Stock Feb 17 2015
Neurocrine Biosciences Reports Year-End 2014 Results and Provides Investor Update for 2015 Feb 16 2015
NEUROCRINE BIOSCIENCES INC Financials Feb 14 2015
10-K for Neurocrine Biosciences, Inc. Feb 11 2015
NBIX: CRF Drug Offers Another Shot on Goal For Catalyst Rich Neurocrine Bio Feb 10 2015
Neurocrine reports 4Q loss Feb 09 2015
Neurocrine reports 4Q loss Feb 09 2015
NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Results of Operations and Financial Condition,... Feb 09 2015
Neurocrine Biosciences Reports Year-End 2014 Results and Provides Investor Update for 2015 Feb 09 2015
Q4 2014 Neurocrine Biosciences Inc Earnings Release - After Market Close Feb 09 2015
NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Change in Directors or Principal Officers Feb 05 2015
Coverage initiated on Neurocrine Biosci by Robert W. Baird Feb 05 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK